NASDAQ:NLNK NewLink Genetics (NLNK) Stock Price, News & Analysis → Crypto Pioneer Says: “The last crypto bull market has begun.” (From InvestorPlace) (Ad) Free NLNK Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.42▼$2.6450-Day Range$0.89▼$14.1052-Week Range$0.82▼$3.60Volume7,451 shsAverage Volume547,540 shsMarket Capitalization$94.81 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get NewLink Genetics alerts: Email Address Ad InvestorPlaceElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. About NewLink Genetics Stock (NASDAQ:NLNK)NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma. The company also develops NLG207 in combination with paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer; NLG802, a prodrug of indoximod, which has completed Phase I clinical trial; and NLG919, a direct enzymatic inhibitor. The company has collaboration and license agreement with Genentech Inc. for the development and commercialization of NLG919, as well as a research collaboration for the discovery of next generation IDO/TDO inhibitors; and Merck Sharpe & Dohme Corp. to research, develop, and commercialize rVSV G-ZEBOV GP, an Ebola vaccine product candidate. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.Read More Ad InvestorPlaceElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. NLNK Stock News HeadlinesMay 17 at 10:01 AM | cnet.comBest DNA Test for 2024May 15 at 12:34 AM | markets.businessinsider.comNewLink Genetics is about to announce earnings — here's what Wall Street expectsMarch 20, 2024 | wsj.comNewlink Technology Inc.March 6, 2024 | markets.businessinsider.comHere's what Wall Street expects from NewLink Genetics's earnings reportDecember 19, 2023 | investing.comNewlink Technology Inc (9600)October 27, 2023 | foxnews.comSuicide and genetics: Study identifies 12 DNA variations that could increase the riskAugust 23, 2023 | forbes.comGenetic Testing Before Pregnancy: What You Need To KnowJune 28, 2023 | thestreet.comWhy NewLink Genetics (NLNK) Stock Is Gaining TodayMay 23, 2023 | fool.comDigimarc (NASDAQ: DMRC)February 15, 2023 | thestreet.comTrade Ebola Stocks? Sure, But Don't Bet on Big Business OpportunityJanuary 17, 2023 | dailymail.co.ukWill parents take up a DNA test to spot rare diseases? Expert predicts genetic codes of babies could be read by the NHS in as little as five yearsJanuary 14, 2023 | thestreet.comJumpstart ASCO '15 With This Quick List of Hot Research AbstractsJanuary 14, 2023 | thestreet.comCorbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed PositiveAugust 3, 2021 | markets.businessinsider.comHere's what Wall Street expects from NewLink Genetics's earningsSee More Headlines Receive NLNK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NewLink Genetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/06/2019Today5/18/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:NLNK CUSIP65151110 CIK1126234 Webwww.newlinkgenetics.com Phone515-296-5555FaxN/AEmployees55Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-42,990,000.00 Net Margins-4,592.84% Pretax MarginN/A Return on Equity-41.50% Return on Assets-33.95% Debt Debt-to-Equity RatioN/A Current Ratio7.98 Quick Ratio7.98 Sales & Book Value Annual Sales$940,000.00 Price / Sales100.87 Cash FlowN/A Price / Cash FlowN/A Book Value$2.11 per share Price / Book1.20Miscellaneous Outstanding Shares37,328,000Free FloatN/AMarket Cap$94.81 million OptionableNot Optionable Beta1.17 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Charles J. Link Jr. (Age 60)Co-Founder, Chairman, CEO & Chief Scientific Officer Mr. Nicholas N. Vahanian (Age 52)Co-Founder, Pres, Chief Medical Officer & Director Dr. Eugene P. Kennedy M.D. (Age 50)FACS, Chief Medical Officer Mr. Brian Wiley (Age 51)Chief Commercial Officer Mr. Carl W. Langren (Age 64)CFO & Principal Accounting Officer Key CompetitorsRegulus TherapeuticsNASDAQ:RGLSBolt BiotherapeuticsNASDAQ:BOLTFortress BiotechNASDAQ:FBIORigel PharmaceuticalsNASDAQ:RIGLMerrimack PharmaceuticalsNASDAQ:MACKView All Competitors NLNK Stock Analysis - Frequently Asked Questions How were NewLink Genetics' earnings last quarter? NewLink Genetics Corp (NASDAQ:NLNK) released its earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.27) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.27). The biotechnology company earned $0.25 million during the quarter. NewLink Genetics had a negative trailing twelve-month return on equity of 41.50% and a negative net margin of 4,592.84%. What other stocks do shareholders of NewLink Genetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other NewLink Genetics investors own include Inovio Pharmaceuticals (INO), Arbutus Biopharma (ABUS), OPKO Health (OPK), Novavax (NVAX), SunPower (SPWR), Synergy Pharmaceuticals (SGYP), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), Cara Therapeutics (CARA) and Gilead Sciences (GILD). This page (NASDAQ:NLNK) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaBreaking News: Elon Musk Invents New Type of A.I. (Shocking)InvestorPlaceI’m afraid WWIII is a very real possibility Porter & CompanyProtect Your Bank Account Before It’s Too LateWeiss RatingsUrgent Nvidia WarningAltimetryExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewLink Genetics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.